NCT02643303: A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers

NCT02643303
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active brain metastases; Patients who had prior treatment with an immune checkpoint blockade (anti-PD-1/ or PD-L1/2 & CTLA-4); Patients with autoimmune disease
https://ClinicalTrials.gov/show/NCT02643303

Comments are closed.

Up ↑